相关实验视频

Updated: Sep 19, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

桑基索巴官员L.和Sophora japonica L.在性结肠炎中抑制血管生成

Wei Yuzhuo¹, Liu Li¹, Bu Shu¹

¹Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.

Journal of gastroenterology and hepatology

|June 16, 2025

概括

桑格苏尔巴 (Sanguisorba officinalis L.) 和日本 (Sophora japonica L.) 通过减少炎症和抑制病态血管生成,有效治疗性结肠炎 (UC). 这项研究揭示了SOSJJ.

科学领域:

药理学和传统医学的医学.
胃肠道学和免疫学
分子生物学和信号通路

背景情况:

传统上,Sanguisorba officinalis L.和Sophora japonica L. (SOSJ) 由于其静血性质,用于治疗性结肠炎 (UC).
对于UC的SOSJ的精确治疗机制在很大程度上仍未被阐明.
这项研究调查了SOSJ对UC的疗效所涉及的分子标和途径.

研究的目的:

阐明Sanguisorba officinalis L.和Sophora japonica L. (SOSJ) 在治疗性结肠炎 (UC) 中的治疗机制.
在实验性UC模型中识别SOSJ调制的分子目标和信号通路.
使用临床前模型验证SOSJ的抗炎和抗血管效应.

主要方法:

使用3%酸 (DSS) 诱导的性结肠炎 (UC) 鼠标模型来评估SOSJ的疗效.
评估一般情况,组织病理学和结肠炎症因素 (IL-6,IL-1β,TNF-α).
通过mRNA表达 (VEGF,VCAM1,Ang1,MMPs),微血管密度和传输电子显微镜评估血管生成;研究PI3K-Akt路径调制.

主要成果:

在DSS诱导的UC小鼠中,SOSJ显著减轻了炎症并抑制了病态血管生成.
观察到一般状况的改善,包括减轻体重减轻,结肠缩短和便异常.
关键炎症媒介 (IL-6,IL-1β,TNF-α) 和血管生成相关因子 (VEGF,VCAM1,Ang1,MMPs) 的表达减少;调节PI3K-Akt通路.

结论:

桑古西尔巴官员L.和Sophora japonica L. (SOSJ) 在性结肠炎 (UC) 的小鼠模型中显示出显著的治疗效果.
观察到的好处归因于血管生成和PI3K-Akt信号通路的调节.
这些发现为SOSJ在治疗UC的传统使用提供了机制基础.

关键词:

这就是PI3K-Akt.血树官员植物L L 苏波拉日本L L 血管新生是因为血管新生.网络药理学网络药理学性结肠炎是一种

更多相关视频

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...